Standard Nuclear STDN
- Market cap
- $1.9B
- PE
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- not a meaningful number
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- n/m
- not a meaningful number
Charts
Financials
| Income statement | Q1 FY25 | Q2 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|
| $377.9K | $552.9K | $593.8K | $4.7M | |
| Cost of revenue | $1.2M | $1.2M | $5M | $1.6M |
| Gross profit | −$779K | −$629.8K | −$4.4M | $3.2M |
| R&D | $0 | $0 | $0 | $2M |
| SG&A | $634.8K | $1M | $3.8M | $5.5M |
| −$1.4M | −$1.6M | −$8.2M | −$4.3M | |
| Pre-tax income | −$8.3M | −$1.6M | −$7.7M | −$3.4M |
| $0 | $0 | $0 | $0 | |
| Net income | −$8.3M | −$1.6M | −$7.7M | −$3.4M |
| −$0.30 | −$0.06 | −$0.28 | −$0.12 | |
| 28M | 28M | 28M | 28M |
Revenue: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.
Cost of revenue: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.
Gross profit: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.
R&D: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.
SG&A: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.
Operating income: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.
Pre-tax income: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.
Income tax: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.
Net income: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.
EPS, diluted: Q1 FY25 and Q1 FY26: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY25 and Q1 FY26: share-days: the 6-month average less the second quarter's.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Chemicals - Specialty nearest Standard Nuclear's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| STDNStandard Nuclear | $1.9B | n/m | n/a | n/m | n/m | n/m | |
| REXREX AMERICAN RESOURCES | $1.3B | 10.9× | 16.8× | 2.0× | +1% | 19.7% | |
| GPREGreen Plains | $979.9M | 8.8× | 26.1× | 0.5× | −24% | 6.8% | |
| WLKPWestlake Chemical Partners | $745.5M | 13.0× | 13.7× | 0.6× | +12% | 4.7% | |
| LXULSB Industries | $712.1M | 19.8× | 7.9× | 1.1× | +22% | 5.6% | |
| SXTSensient Technologies | $5.6B | 35.8× | 29.8× | 3.3× | +8% | 9.3% | |
| AXTAAxalta Coating Systems | $7.3B | 21.1× | 28.3× | 1.4× | −1% | 6.8% | |
| LXFRLuxfer | $462.4M | 59.6× | 22.4× | 1.3× | −11% | 2.2% | |
| NEUNewmarket | $8B | 18.7× | 16.8× | 2.9× | −1% | 15.8% | |
| CLXClorox | $10.4B | 17.9× | 26.3× | 1.6× | −5% | 8.7% | |
| RPMRPM International | $12.6B | 18.3× | 25.5× | 1.6× | +6% | 8.7% | |
| Peer median | $3.5B | 18.5× | 24.0× | 1.5× | +0% | 7.7% |
More on Standard Nuclear
Each number over time
Its groups
About
- Industry
- Chemicals - Specialty
- Sector
- Basic Materials
Valuation data, not investment advice. Prices as of .